Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T3-4-Hypo trial: LT4/LT3 combination vs LT4 monotherapy in autoimmune hypothyroidism
2024-513883-24-00Phase 3Authorised
- Sponsor
- Erasmus MC
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liothyronine and levothyroxine sodium in autoimmune thyroiditis and hypothyroidism (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary: Change in ThyPRO tiredness subscale score at 52 weeks. Planned start Nov 2025; status: authorised.
02
Drugs
liothyroninelevothyroxine sodium
03
Conditions
autoimmune thyroiditishypothyroidism
Beyond the preview
Go deeper on 2024-513883-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513883-24-00.